Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04126096 · ClinicalTrials.gov registry record · NA
Negative Predictive Value and NIC of Beta-Lactam Antibiotics.
A NA study, sponsored by Mayo Clinic.
- Completed
- Registry status
- NA
- Development phase
- 747
- Enrollment target
NCT04126096: Completed NA study, sponsored by Mayo Clinic.
NCT04126096 is a NA study that has completed, run by Mayo Clinic. The registered enrollment target is 747 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (47% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04126096, a NA study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- NA
- Development phase
- 747 participants
- Enrollment target
Study Summary
The researchers are trying to evaluate how much medication is required for allergy skin testing and to determine the likelihood that patients with a negative test truly don't have an allergy to the tested drug of skin testing to commonly used antibiotics.
Primary Outcome
Determine the NIC to common beta lactam containing antibiotics
Interventions
- DIAGNOSTIC_TEST Skin Testing beta-lactams
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 747 participants |
| Start Date | 2019-09-20 |
| Est. Completion | 2023-01-06 |
| Phase | NA |
What the finished NCT04126096 record still lists
NCT04126096 is an interventional study that assigns participants to a tested intervention. The registered 747 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (47% lower).
The record links to 0 conditions, and to 1 intervention - of which Skin Testing beta-lactams is the first listed.
NCT04126096 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04126096 about?
NCT04126096 is a clinical study titled "Negative Predictive Value and NIC of Beta-Lactam Antibiotics.". The researchers are trying to evaluate how much medication is required for allergy skin testing and to determine the likelihood that patients with a negative test truly don't have an allergy to the tested drug of skin testing to commonly used antibiotics.
What is the current status of trial NCT04126096?
This trial is currently completed. It is a NA study. The enrollment target is 747 participants. The study started on 2019-09-20. Estimated completion is 2023-01-06.
What interventions are being tested in trial NCT04126096?
The interventions under investigation include: Skin Testing beta-lactams (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04126096?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04126096's enrollment target sits among peer trials
747 145th of 2000 higher than 1,856 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02048332 · 750 participants · Phase 1
Donor-Derived Viral Specific T-cells (VSTs)
- NCT02087852 · 750 participants
Kidney Cancer DNA Registry
- NCT02532452 · 750 participants · Phase 2
Third Party Viral Specific T-cells (VSTs)
- NCT03126916 · 750 participants · Phase 3
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI